Welcome to our dedicated page for Briacell Therapeutics news (Ticker: BCTX), a resource for investors and traders seeking the latest updates and insights on Briacell Therapeutics stock.
Briacell Therapeutics Corp (BCTX) is a clinical-stage biotechnology company pioneering novel immunotherapies for cancer treatment. This page serves as the definitive source for verified news and official updates regarding the company’s research initiatives, clinical trial progress, and strategic developments.
Investors and industry professionals will find timely updates on key programs including the Bria-IMT Phase 3 trial for metastatic breast cancer and the Bria-OTS platform’s expansion into additional oncology applications. The resource consolidates press releases, regulatory filings, and partnership announcements to provide comprehensive tracking of the company’s progress in immuno-oncology.
Content highlights include clinical trial milestones, peer-reviewed research publications, manufacturing updates, and executive commentary. All materials are sourced directly from company disclosures to ensure accuracy and compliance with financial reporting standards.
Bookmark this page for streamlined access to Briacell’s latest developments in targeted cell-based immunotherapies. Check regularly for updates on pivotal studies and emerging data from their innovative cancer treatment platforms.
BriaCell Therapeutics (Nasdaq: BCTX) has announced the pricing of a $13.8 million public offering consisting of 3,066,666 units, including 399,999 units from the full exercise of the underwriter's option. Each unit, priced at $4.50, includes one common share (or pre-funded warrant) and one warrant.
The warrants, trading under symbol 'BCTXZ' from April 25, 2025, are immediately exercisable at $5.25 per share with a five-year expiration. The offering is expected to close on April 28, 2025. ThinkEquity serves as the sole book-running manager.
The company plans to utilize the net proceeds for working capital requirements, general corporate purposes, and advancing business objectives.
BriaCell Therapeutics (Nasdaq: BCTX) has confirmed complete resolution of lung metastasis in their Phase 1/2a Bria-OTS study. The breakthrough was observed in a 78-year-old woman with hormone receptor positive (HR+) metastatic breast cancer who had previously failed multiple therapies.
The patient, enrolled on November 21, 2024, received Bria-OTS intradermal injections every 2 weeks for six weeks (4 doses), followed by dosing every 3 weeks. The treatment resulted in complete resolution of lung metastasis at 2 months, confirmed at 4 months follow-up, with stable disease maintained elsewhere.
The patient entered the study with extensive metastases in bone, lymph node, and lung. This response was achieved with the lowest dose level in the trial, demonstrating promising activity of the Bria-OTS platform as monotherapy. The Phase 1/2a dose escalation study (NCT06471673) will evaluate Bria-OTS both as monotherapy and in combination with an immune checkpoint inhibitor.
BriaCell Therapeutics (Nasdaq: BCTX) has announced four clinical data presentations at the upcoming 2025 ASCO Annual Meeting in Chicago. The presentations include three poster sessions and one publish-only abstract, all focusing on breast cancer treatments.
The presentations will showcase: 1) An update on the phase III pivotal trial of Bria-IMT combined with checkpoint inhibitor versus physician's choice in advanced metastatic breast cancer; 2) Phase I/II survival results of Bria-IMT with checkpoint inhibitor compared to benchmark trials; 3) A trial-in-progress study of Bria-OTS cellular immunotherapy in metastatic recurrent breast cancer; and 4) A publish-only abstract on HLA Matching impact on clinical outcomes in Phase 2 trials.
All poster presentations are scheduled for June 2, 2025, from 9:00 AM to 12:00 PM CDT. The abstracts will be released on May 22, 2025, at 5:00 PM ET, with presentations later available on BriaCell's website.
BriaCell Therapeutics (Nasdaq: BCTX) reports accelerating enrollment in its pivotal Phase 3 clinical study for advanced metastatic breast cancer treatment. The study has enrolled over 75 patients across 54 clinical sites in 15 states, evaluating Bria-IMT plus immune checkpoint inhibitor versus physician's choice.
The company expects to complete patient enrollment by late 2025 or early 2026, with potential top-line data release in H1-2026. The study's primary endpoint compares overall survival between treatment groups, with interim analysis planned after 144 patient events. The Bria-IMT combination regimen has received FDA Fast Track designation, and positive Phase 3 results could lead to full approval and marketing authorization for metastatic breast cancer treatment.
BriaCell Therapeutics (Nasdaq: BCTX) has announced promising Phase 2 survival data for its Bria-IMT™ treatment in metastatic breast cancer patients. The study showed a median overall survival of 17.3 months in hormone receptor positive (HR+) patients, surpassing TRODELVY®'s 14.4 months in similar heavily pre-treated cases.
The Phase 2 trial included 54 patients with a median of 6 prior treatments. Of these, 37 received the current Phase 3 formulation, with 25 identified as HR+ breast cancer patients. In triple negative breast cancer (TNBC) patients, Bria-IMT showed comparable results to TRODELVY® with 11.4 months versus 11.8 months survival, both significantly higher than chemotherapy's 6.9 months.
Notably, no Bria-IMT related discontinuations have been reported in the ongoing pivotal Phase 3 study (NCT06072612), suggesting good tolerability.
BriaCell Therapeutics Corp (Nasdaq: BCTX, BCTXW) and its subsidiary BriaPro have announced the development of novel antibodies targeting B7-H3, a significant cancer antigen and immune checkpoint molecule. The technology, for which US patent applications have been filed, aims to create antibody-drug conjugates, T cell engagers, and targeted immune checkpoint inhibitors.
B7-H3 is highly expressed on both tumor and immune cells, making it an ideal target for cancer treatment. The protein is overexpressed in various solid tumors, including prostate, lung, breast, pancreatic, and ovarian cancers, while showing expression in normal tissues. BriaPro plans to incorporate these antibodies into its Bria-TILsRx™ platform, designed to redirect and activate T cells within the tumor microenvironment.
BriaCell Therapeutics (Nasdaq: BCTX) has announced its upcoming presentation of three posters at the 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago from April 25-30.
The presentations include: 1) Results from Bria-ABC1 versus physician choice in late-stage MBC with biomarker correlates from the randomized registration trial; 2) Survival outcomes from a randomized phase 2 trial of Bria-IMT, an allogeneic whole cell cancer vaccine; and 3) Findings on Bria-OTS+, described as a versatile therapeutic platform for inducing anti-cancer immunity.
The posters will be presented across different sessions focusing on clinical research, Phase II/III trials, and immunology. Following the presentations, the posters will be made available on BriaCell's website.
BriaCell Therapeutics (Nasdaq: BCTX) received a positive recommendation from the Data Safety Monitoring Board (DSMB) for its pivotal Phase 3 study of Bria-IMT™ plus immune checkpoint inhibitor in metastatic breast cancer. The DSMB, an independent expert group, completed its second safety data review and found no safety concerns, recommending the continuation of the ongoing study without modifications.
The study is being conducted under Fast Track Designation from the FDA. The company's management expressed satisfaction with the safety and tolerability profile of the Bria-IMT plus immune checkpoint inhibitor combination therapy, viewing the DSMB's recommendation as an encouraging sign for their novel immunotherapy approach to treating metastatic breast cancer.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) held its annual general meeting on February 5, 2025, for the fiscal year ended July 31, 2024. The meeting saw a 36.26% participation rate of issued and outstanding common shares. Shareholders strongly supported all proposed resolutions, including the re-appointment of MNP LLP as auditors and the election of board directors.
The elected board members, all receiving over 86% approval, include Dr. William V. Williams (88.42%), Mr. Jamieson Bondarenko (86.57%), Dr. Jane A. Gross (88.37%), Dr. Rebecca Taub (88.44%), Mr. Vaughn C. Embro-Pantalony (88.05%), and Mr. Martin E. Schmieg (87.99%).
BriaCell Therapeutics (Nasdaq: BCTX) has completed its previously announced best-efforts public offering, selling 762,500 common shares at $4.00 per share, raising gross proceeds of $3.05 million. The offering was conducted under the Company's effective shelf registration statement on Form S-3, with ThinkEquity serving as the sole placement agent.
The clinical-stage biotechnology company, which develops novel immunotherapies for cancer treatment, plans to utilize the net proceeds for working capital requirements, general corporate purposes, and advancing its business objectives. The offering was executed under the TSX Company Manual Section 602.1 exemption, applicable to eligible interlisted issuers on recognized exchanges like Nasdaq.
